Evidence map›Paper›PMID 42274775›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2026

Prognostic impact of iliofemoral access-site calcification volume on outcomes after transcatheter aortic valve implantation.

Vivian Vij, Katja Schauwienold, Jasmin Shamekhi, Samuel Muli, Mustafa Basha, Eleftherios Markidis, Andreas Zietzer, Philip Düsing, Muntadher Al Zaidi, Marcel Weber and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Vivian VijHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Katja SchauwienoldHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Jasmin ShamekhiHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Samuel MuliHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Mustafa BashaHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Eleftherios MarkidisHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Andreas ZietzerHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Philip DüsingHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Muntadher Al ZaidiHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Marcel WeberHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Lara Al-KassouCenter for Cardiovascular Medicine of the Heart Centers Aachen, Bonn, Cologne and Duesseldorf - CCM ABCD, Cologne, Germany.
Tobias ZeusCenter for Cardiovascular Medicine of the Heart Centers Aachen, Bonn, Cologne and Duesseldorf - CCM ABCD, Cologne, Germany.
Victor MauriCenter for Cardiovascular Medicine of the Heart Centers Aachen, Bonn, Cologne and Duesseldorf - CCM ABCD, Cologne, Germany.
Matti AdamCenter for Cardiovascular Medicine of the Heart Centers Aachen, Bonn, Cologne and Duesseldorf - CCM ABCD, Cologne, Germany.
Jörg SchröderCenter for Cardiovascular Medicine of the Heart Centers Aachen, Bonn, Cologne and Duesseldorf - CCM ABCD, Cologne, Germany.
Stephan BaldusCenter for Cardiovascular Medicine of the Heart Centers Aachen, Bonn, Cologne and Duesseldorf - CCM ABCD, Cologne, Germany.
Malte KelmCenter for Cardiovascular Medicine of the Heart Centers Aachen, Bonn, Cologne and Duesseldorf - CCM ABCD, Cologne, Germany.
Nikolaus MarxCenter for Cardiovascular Medicine of the Heart Centers Aachen, Bonn, Cologne and Duesseldorf - CCM ABCD, Cologne, Germany.
Farhad BakhtiaryCenter for Cardiovascular Medicine of the Heart Centers Aachen, Bonn, Cologne and Duesseldorf - CCM ABCD, Cologne, Germany.
Enzo LüsebrinkHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Sebastian ZimmerHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Georg NickenigHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Alexander SedaghatHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Baravan Al-KassouHeart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. Baravan.al-kassou@ukbonn.de.ORCID http://orcid.org/0000-0003-2967-6613

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTranscatheter aortic valve implantation (TAVI) is increasingly performed in patients at low and intermediate risk, emphasizing the need for accurate long-term risk stratification. Although iliofemoral calcification influences procedural planning, its prognostic relevance beyond peri-procedural complications remains uncertain.

objectivesTo evaluate the prognostic value of quantitatively assessed iliofemoral access-site calcification (IASC) for outcomes after TAVI.

methodsThe study included 1067 patients undergoing TAVI. Pre-procedural computed tomography (CT) was used to quantify IASC-volume along the transfemoral access route. Patients were stratified according to the median IASC-volume, and outcomes were compared using propensity score matching (PSM). The primary endpoint was all-cause mortality at 1, 3, and 5 years. Secondary endpoints included peri-procedural complications at 30 days.

resultsThe median IASC-volume was 907 (356-1839) mm

conclusionCT-derived IASC-volume is associated with mid- and long-term mortality after TAVI, without affecting short-term or procedural outcomes. These findings suggest that IASC-volume reflects systemic disease burden and may provide incremental prognostic information beyond established risk scores.

Indexed as

Iliofemoral calcificationLong-term mortalityTAVIVascular complications

Identifiers

PMID42274775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.